预约演示
更新于：2025-12-10
Belatacept
贝拉西普
更新于：2025-12-10
概要
基本信息
药物类型 Fc融合蛋白 |
别名 Belatacept (USAN/INN)、BMS-224818、L104EA29YIG + [4] |
作用方式 抑制剂 |
作用机制 CD80抑制剂(分化群80抑制剂)、CD86抑制剂(分化群86抑制剂) |
治疗领域 |
非在研机构- |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (2011-06-15), |
最高研发阶段(中国)- |
特殊审评孤儿药 (美国) |
登录后查看时间轴
结构/序列
Sequence Code 5028
来源: *****
关联
84
项与 贝拉西普 相关的临床试验NCT06918990
Targeting the B Cell Response to Treat Antibody-Mediated Rejection With Carfilzomib and Belatacept (CarBel)
CTIS2024-516527-13-00
Screening for subclinical antibody mediated rejection and efficacy of belatacept in the context of de novo donor specific antibody after kidney transplantation / BEL-AMR
CTIS2024-517219-56-00
Safety and efficacy of steering of immunosuppression based on BKPyV-specific T cells in case of BK Polyomavirus (BKPyV) DNAe- mia after kidney transplantation
100 项与 贝拉西普 相关的临床结果
登录后查看更多信息
100 项与 贝拉西普 相关的转化医学
登录后查看更多信息
100 项与 贝拉西普 相关的专利（医药）
登录后查看更多信息
379
项与 贝拉西普 相关的文献（医药）2026-02-01TRANSPLANT IMMUNOLOGY
Conversion to belatacept-based immunosuppression as a calcineurin sparing regimen in lung transplant: A multi-institutional retrospective study
Article
作者: Bollineni, Srinivas ; Saha, Biplab ; Miller, Cecelia M ; Ishaq, Ariana ; Emtiazjoo, Amir ; Torres, Fernando ; Aladaileh, Mohammad A ; Timofte, Irina ; Rackauskas, Mindaugas ; Gries, Cynthia ; Kaza, Vaidehi ; Kumar, Pooja ; Mederos, Christopher I ; Younis, Moustafa ; Reams, Victoria
BACKGROUND:
Calcineurin inhibitor (CNI) related kidney dysfunction is common and associated with worse outcomes after lung transplantation (LTx). To mitigate that risk, belatacept use in a CNI-sparing regimen is an alternative in LTx. We aim to describe our experience using belatacept as a CNI-sparing regimen in LTx.
METHODS:
A multi-institutional retrospective review of LTx patients who received belatacept (1/2018-8/2023) was performed. The primary outcome is the change in estimated glomerular filtration rate (eGFR) after initiation of belatacept. Secondary outcomes were compared with a control group of patients transplanted during 1/2018-8/2023 that did not receive belatacept. Secondary outcomes include acute cellular rejection (ACR), denovo donor specific antibodies (DSA), antibody mediated rejection (AMR), infections, malignancy, chronic lung allograft dysfunction (CLAD) and mortality.
RESULTS:
A total of 170 LTx patients who received belatacept were included for the primary outcome. To investigate the secondary outcomes an additional 288 LTx controls were used. The median (IQR) eGFR at the time of belatacept initiation, six months, and one year post belatacept initiation was 43 (34-52), 46 (37-53) and 43 (36-53) mL/min/1.73 m2, respectively (p = 0.21). There was no significant difference in ACR, DSA, AMR, infections, malignancy, CLAD or mortality between both groups.
CONCLUSIONS:
Belatacept CNI-sparing therapy was well tolerated and feasible in LTx recipients, with renal function appearing to stabilize over time and no apparent safety signal for acute rejection, infection, malignancy, CLAD, or mortality.
2025-12-01TRANSPLANTATION PROCEEDINGS
Patient Satisfaction With Belatacept Therapy: A Single-Center, Cross-Sectional Study
Article
作者: Santeusanio, Andrew ; Sridhar, Abhinaya ; Farouk, Samira S ; Rademacher, Emily ; Armenti, Jonathan
BACKGROUND:
The efficacy of belatacept for maintenance immunosuppression after kidney transplantation is well-established in the literature. Although this medication is being increasingly used as a strategy to avoid calcineurin inhibitors, which are associated with numerous adverse effects, patient satisfaction with monthly belatacept infusions is not well understood.
METHODS:
We administered a validated treatment satisfaction tool (SATMED-Q) to kidney transplant recipients aged 17 to 85 years, who were receiving monthly belatacept infusions at a single health system-affiliated infusion center.
RESULTS:
A total of 74 patients were approached for the study, and 70 completed the survey. The overall satisfaction score was 86.6/100. Scores for satisfaction with medical follow-up and impact on everyday life were 96.9 and 76.7, respectively. Patients also reported high scores in relation to side effects (94.2), general opinion (94.1), and convenience (81.8).
CONCLUSIONS:
Patients with kidney transplants reported very high satisfaction scores with belatacept use, with almost 100% patients intending to continue belatacept therapy.
2025-11-01Kidney International Reports
Shiga Toxin–Producing Escherichia coli–Associated Hemolytic Uremic Syndrome in Adult Kidney Transplant Recipients
Article
作者: Kaminski, Hannah ; Provôt, François ; Ville, Simon ; Bouvier, Nicolas ; Mariani, Patricia ; Rafat, Cédric ; Caillard, Sophie ; Zuber, Julien ; Baili, Nesrine ; Scemla, Anne ; Legendre, Christophe ; Lefevre, Edouard ; Bertrand, Dominique ; Touré, Fatouma ; Westeel, Pierre-François ; Kamar, Nassim ; Martinez, Frank ; Sberro-Soussan, Rebecca ; Gamot, Roxane ; Chauvet, Sophie ; Bonacorsi, Stéphane ; Mazloum, Manal ; Cointe, Aurélie ; Trémolières, Pierre ; Anglicheau, Dany ; Le Quintrec, Moglie ; Levi, Charlene
Introduction:
Shiga toxin (Stx)-producing Escherichia coli (E coli)-associated hemolytic uremic syndrome (STEC-HUS) is an acquired form of thrombotic microangiopathy (TMA) caused by food and waterborne infection. It remains the leading cause of acute renal injury (AKI) in children. In adults, STEC-HUS is less common but often more severe. Data on STEC-HUS in kidney transplant recipients (KTRs) are limited.
Methods:
We conducted a retrospective study involving adult KTRs diagnosed with STEC-HUS between January 2012 and April 2022 across 15 French nephrology centers. We aimed to characterize the clinical, biological, and microbiological features of STEC-HUS in this population, its management, and outcomes.
Results:
A total of 35 adult KTRs were included. The annual incidence was estimated at 14.4 cases per 100,000 KTRs. Six and 29 patients presented with localized intrarenal or systemic TMA, respectively. The median time from transplantation to STEC-HUS diagnosis was 3 (1.2-6.2) years and the mean age at diagnosis was 57 ± 13 years. Neurological and cardiac complications occurred exclusively in patients with systemic TMA. AKI and significant proteinuria were observed in 89% and 94% of patients, respectively. All patients requiring dialysis exhibited systemic TMA (38%). Treatment included azithromycin, eculizumab, and conversion from calcineurin inhibitors (CNIs) to belatacept. Graft loss and mortality rates were 26% and 9%, respectively.
Conclusion:
This study highlights that STEC-HUS represents a serious complication in KTRs, significantly impairing renal and overall survival. It should be systematically considered in cases of de novo posttransplant TMA, whether in the absence of prodromal diarrhea or in localized intra-renal presentations.
100 项与 贝拉西普 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 肾移植排斥反应 | 美国 | 2011-06-15 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 同种异体移植排斥反应 | 临床3期 | 美国 | 2021-07-21 | |
| 同种异体移植排斥反应 | 临床3期 | 阿根廷 | 2021-07-21 | |
| 同种异体移植排斥反应 | 临床3期 | 比利时 | 2021-07-21 | |
| 同种异体移植排斥反应 | 临床3期 | 法国 | 2021-07-21 | |
| 同种异体移植排斥反应 | 临床3期 | 德国 | 2021-07-21 | |
| 同种异体移植排斥反应 | 临床3期 | 意大利 | 2021-07-21 | |
| 同种异体移植排斥反应 | 临床3期 | 荷兰 | 2021-07-21 | |
| 同种异体移植排斥反应 | 临床3期 | 挪威 | 2021-07-21 | |
| 同种异体移植排斥反应 | 临床3期 | 西班牙 | 2021-07-21 | |
| 同种异体移植排斥反应 | 临床3期 | 英国 | 2021-07-21 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 5 | 鏇觸鹽襯醖鏇壓衊繭選(夢觸襯淵窪膚淵淵選廠) = One recipient discontinued belatacept after 11 months due to infusion-related dizziness and post-infusion somnolence; no other adverse effects were observed. 繭壓夢獵鹽積憲壓網鹽 (願夢襯窪糧膚觸築醖襯 ) 更多 | 积极 | 2025-11-08 | |||
临床1期 | 维持 donor-specific antibody (DSA) | - | 鏇願襯齋選簾壓鏇鹽選(鑰蓋願鏇衊鏇餘積築襯) = Donor-MSC infusion was acutely well-tolerated in humans and NHPs 構獵衊鹽醖製鑰選觸夢 (選獵網築遞壓簾淵艱餘 ) 更多 | 不佳 | 2025-05-01 | ||
N/A | 55 | 範築選窪衊願鏇鑰鏇醖(選醖顧獵範廠觸襯壓築) = 遞獵壓衊餘築積蓋夢製 醖鬱齋壓鬱齋鬱憲積簾 (簾鹹遞窪夢憲顧窪夢膚 ) 更多 | 积极 | 2024-10-24 | |||
N/A | 311 | 夢衊願顧衊獵繭遞鏇鏇(艱艱鬱繭繭齋選膚鬱繭) = 餘鹽廠積醖淵築壓壓醖 顧範鏇醖襯餘簾積鹽壓 (繭鹹簾鏇選繭網簾廠夢 ) 更多 | 积极 | 2024-05-01 | |||
Calcineurin Inhibitors (CNI) | 夢衊願顧衊獵繭遞鏇鏇(艱艱鬱繭繭齋選膚鬱繭) = 鹽鹹廠廠糧憲衊繭遞製 顧範鏇醖襯餘簾積鹽壓 (繭鹹簾鏇選繭網簾廠夢 ) 更多 | ||||||
N/A | - | Tacrolimus to Belatacept Conversion | 鏇獵鏇餘襯鑰築壓夢窪(廠願糧簾衊簾餘積憲膚) = 蓋顧積鹹衊築艱醖製遞 憲願鹽積範憲獵鹽壓窪 (顧鹹窪範廠餘糧選淵夢 ) 更多 | 积极 | 2024-04-01 | ||
临床2期 | donor-specific antibodies (DSA) | 27 | Belatacept arm | 構齋齋廠獵繭餘觸鹽膚(網壓蓋築鏇獵鹹廠鏇糧) = 築糧選淵窪夢壓憲範衊 醖簾簾遞壓觸繭選選構 (蓋鏇選構餘夢鑰壓齋顧 ) | 不佳 | 2024-03-01 | |
临床4期 | 17 | Allosure | 構艱鬱艱築膚憲鹹鑰醖 = 淵繭鬱觸餘壓築觸積鏇 衊夢遞廠願艱鏇廠網夢 (廠淵糧顧選膚願網窪製, 夢範遞觸廠顧選憲積製 ~ 築繭簾築簾築獵簾憲鏇) 更多 | - | 2023-12-04 | ||
临床4期 | 20 | 衊築繭膚範廠糧醖襯觸 = 築選簾壓糧糧積鏇製壓 製糧鑰鬱蓋餘蓋膚鹹築 (範觸製餘遞壓選鑰齋壓, 餘鹹鑰簾簾膚積鏇鏇獵 ~ 餘艱壓顧壓膚範蓋鹽鑰) 更多 | - | 2022-12-13 | |||
临床2期 | 15 | 齋憲構齋窪壓鑰壓觸蓋 = 襯蓋鑰製選鑰繭窪鑰繭 鹹糧窪範觸夢觸壓窪觸 (壓鏇齋醖艱選襯範願積, 蓋夢蓋網選窪願遞淵選 ~ 憲蓋選壓鹽憲顧襯膚製) 更多 | - | 2022-11-09 | |||
临床2期 | 27 | (Standard of Care) | 構糧積範獵鏇蓋壓願顧 = 齋蓋鏇選顧觸壓製遞壓 襯獵鑰淵繭鑰鏇齋鹹顧 (鏇顧鏇襯廠廠鹽網構衊, 夢蓋簾顧憲廠艱範選鬱 ~ 鏇廠夢鹹繭壓觸艱鹽簾) 更多 | - | 2021-11-02 | ||
(Belatacept-based Immunosuppression) | 構糧積範獵鏇蓋壓願顧 = 糧廠積製憲憲夢繭衊觸 襯獵鑰淵繭鑰鏇齋鹹顧 (鏇顧鏇襯廠廠鹽網構衊, 積鏇遞顧壓網鏇範廠壓 ~ 鏇繭構鏇鹹餘蓋壓顧廠) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
生物类似药
生物类似药在不同国家/地区的竞争态势。请注意临床1/2期并入临床2期，临床2/3期并入临床3期
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用